BioPharm International's BP Elements, May 2022

Further development of nucleic acid-based therapeutics has been accelerated by the recent success of mRNA vaccines.

Outsourcing partners are ready to fill the market need for greater cell therapies capacities.

908 Devices and CPI have formed a collaboration to optimize cell culture media to allow for improved process control.

Lonza and Integral Molecular will collaborate to better assess the risks of off-target binding of biologic drug candidates.

MilliporeSigma’s ZooMAb antibodies have been recognized for their low environmental impact by My Green Lab.

Standard BioTools’ new Hyperion+ Imaging System can process more samples and has lower limits of detection than their current product.

Bio-Rad Laboratories introduces three new fluorescent dyes under the StarBright product range to support multicolor flow cytometry panels.

Otsuka Pharmaceutical and Osaka University have entered an exclusive license agreement on a new anti-tumor antibody.

Thermo Fisher Scientific has launched its first GMP-manufactured Cas9 protein for clinical genome editing research.

VectorBuilder will expand with the construction of new $500 million Gene Delivery Research and Manufacturing Campus in Guangzhou, China.

Biomarker-guided trial led by University Hospital Hamburg-Eppendorf (UKE) opens new avenues for personalized medicine for treatment of COVID-19.